Özdemir, AyferOrhan, ErkanAltun, Serdarİnözü, Emre2022-05-112022-05-1120172000-656X2000-6764https://doi.org/10.1080/2000656X.2016.1237958https://hdl.handle.net/20.500.11776/8450Objective: Transverse Rectus Abdominis Myocutaneous (TRAM) flap is commonly used in breast reconstruction. The aim of this study is to demonstrate the effects of cilostazol on TRAM flap viability in a rat TRAM model. Methods: Twenty-four Wistar rats were used. They were divided into four groups. Rats in Group 1 were applied TRAM flap. In Group 2, cilostazol 30 mg/kg was administered to rats via oral gavage 3 hours before the flap surgery. After the flap surgery, cilostazol 30mg/kg was administered via oral gavage twice a day for 7 days. In Group 3 before the flap surgery, cilostazol 30 mg/kg was administered via oral gavage twice a day for 7 days, and treatment continued for 7 more days after the flap surgery. In Group 4 before the flap surgery, cilostazol 30 mg/kg was administered via oral gavage twice a day for 7 days and treatment was discontinued after the flap surgery. Result: The mean necrosis rate in Group 1 was 41.69%, in Group 2 it was 27.0%, in Group 3 it was 6.66%, and in Group 4 it was 11.2%. The necrosis rate in Group 1 was found to be statistically significantly higher than other groups (p < .01), the necrosis rate in Group 2 was found to be statistically significant higher than Groups 3 and 4 (p < .01), and the necrosis rate in Group 4 was found to be statistically significant higher than Group 3 (p < .01). Conclusion: Cilostazol treatment seemed to increase the viability of TRAM flap, especially when administered as adjuvant therapy.en10.1080/2000656X.2016.1237958info:eu-repo/semantics/closedAccessTRAM flapcilostazolflap viabilityEndothelial Growth-FactorTram FlapMusculocutaneous FlapIntermittent ClaudicationModelReconstructionInhibitorViabilityIschemiaFlowArticle513217222Q4WOS:0004015176000112-s2.0-8499017434727707079Q2